TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In an October 27, 2026, article for Being Patient, geriatrician Dr. Nathaniel Chin argues that persistent subjective cognitive decline can be a reason for a fuller evaluation and repeat testing, even when standard scores are normal. He stresses that subjective decline does not diagnose Alzheimer’s and can have many other causes; the supplied report excerpt ends before its discussion of biomarkers is complete.
Geriatrician and memory-care physician Dr. Nathaniel Chin says persistent concerns about memory or thinking can warrant a detailed cognitive assessment and follow-up, even when test scores remain in the normal range. In an article published by Being Patient on October 27, 2026, Chin describes subjective cognitive decline as a possible early point for evaluation and risk-focused care—not as proof that a person has Alzheimer’s disease.
Subjective cognitive decline (SCD) refers to a person’s persistent sense that their cognitive abilities have worsened compared with their previous level, despite testing that does not show objective impairment. Chin says patients may report forgetting conversations, relying more on notes or finding that thinking takes greater effort. Normal scores do not necessarily settle whether an individual has experienced a meaningful change: standard assessments commonly compare people with others of similar age, rather than measuring them against their own earlier abilities.
Chin distinguishes a brief screening from a comprehensive cognitive evaluation. He says screenings often take five to 15 minutes and sample a limited range of abilities. A fuller assessment typically lasts an hour or more and can examine memory, language, attention and executive functions such as planning and shifting between tasks. In his view, establishing a strong baseline and repeating tests over time can help clinicians see whether someone remains stable or shows a consistent decline.
SCD is a description of an experience, not an explanation for it. Chin lists sleep problems, medications, depression or anxiety, illness, vascular disease, hearing loss, stress and normal aging as possible contributors to how sharp a person feels. He recommends looking for those factors rather than assuming Alzheimer’s is responsible. The article excerpt also introduces blood tests, cerebrospinal fluid testing and amyloid PET as ways to assess Alzheimer’s-related biology in selected patients, but does not provide the full discussion or criteria for using them.
When Memory Concerns Need Follow-Up
The practical point in Chin’s account is that normal test results do not always end the clinical question. A person whose abilities were previously well above average could lose ground and still score in the average range, he writes. That possibility makes a personal history and repeat assessment useful parts of the conversation, especially when concerns persist or are corroborated by someone close to the patient.
Chin describes the period between noticing a change and meeting criteria for measurable impairment as a potential opportunity to investigate causes and discuss prevention. That is a clinical perspective, not evidence in the supplied material that SCD itself predicts Alzheimer’s in a particular person or that a specific intervention will prevent the disease. For readers, the distinction matters: a concern deserves a careful response, but it should not be treated as a diagnosis.
The approach may also help avoid two opposite errors: dismissing a person’s experience solely because a brief test is normal, or attributing every memory lapse to Alzheimer’s. Chin’s proposed response is more complete assessment, attention to alternative causes and monitoring over time. Decisions about further testing depend on individual circumstances and should be made with a qualified clinician.
Products Worth Considering
Levoit Core 400S-P Smart Air Purifier for Large Rooms
Levoit Eleva 300X HEPA Air Purifier for Home and Bedroom
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
How Chin Defines SCD Plus
Chin refers to the “SCD plus” concept developed by psychiatrist Frank Jessen and colleagues in the international Subjective Cognitive Decline Initiative. The features described in the article include memory-focused concerns, onset within the previous five years, onset at age 60 or older, worry about the change, persistence, seeking medical help and confirmation from someone who knows the person well.
These features are presented as reasons for closer attention, not as a diagnostic checklist. Chin says none proves Alzheimer’s disease, though several occurring together may raise concern. His comparison is between a person with intermittent word-finding worries over many years, often during stress or poor sleep, and someone in their 60s reporting a clear, persistent memory change that a spouse also observes. Both could score in the normal range, but he says their situations call for different clinical consideration.
The article’s title frames SCD as an early window for prevention and treatment, while its available text focuses on how to recognize concerns and assess them. The supplied excerpt stops partway through the biomarker section, so it does not establish what tests Chin recommends, who should receive them or what treatment choices might follow.
What SCD Cannot Establish
SCD alone cannot determine whether Alzheimer’s is present, and the article lists several other possible explanations for perceived cognitive changes. The source material provides no patient-level risk estimate, diagnostic accuracy figures or evidence that a particular person with SCD will develop impairment. The SCD-plus features are described as indicators that may warrant closer attention; they are not presented as proof.
The available article text cuts off as Chin begins discussing blood biomarkers, cerebrospinal fluid tests and amyloid PET. It therefore does not show his full account of how those tests should be selected or interpreted, nor any specific prevention or treatment recommendation. The source also does not report new research findings or a change in clinical guidelines. Readers should not infer from the title that these tests or treatments are appropriate for everyone who notices memory changes.
Clinical Assessment and Follow-Up
For someone reporting ongoing changes, Chin’s article points toward a clinician-led assessment: establish the nature and timeline of the concern, consider other health or lifestyle contributors, seek observations from a trusted person when appropriate, and decide whether fuller testing or repeat assessment is warranted. Changes over time, rather than one normal screening result alone, are central to the approach he describes.
Whether additional testing is useful will depend on the individual and the clinician’s evaluation. The supplied source does not announce a scheduled study, policy change or next milestone. Further details about biomarker use and treatment would require the full article or additional source material; for now, the supported takeaway is to take persistent concerns seriously without equating them with an Alzheimer’s diagnosis.
Key Questions
What is subjective cognitive decline?
SCD is a persistent feeling that memory or another thinking ability has worsened compared with a person’s earlier level, even though testing does not show objective impairment.
Does subjective cognitive decline mean someone has Alzheimer’s?
No. Chin says SCD is a description of a person’s experience, not its cause. Sleep, medication effects, mood, illness, vascular conditions, hearing loss, stress and normal aging can also affect perceived thinking ability.
Why might a normal test not resolve the concern?
A short screening samples a limited set of abilities, and scores are generally compared with people of similar age. Someone may have declined from a higher personal baseline while still scoring within the average range, according to Chin.
What does SCD plus mean?
It describes features that may make subjective decline more concerning, such as persistent, memory-focused changes beginning later in life and noticed by someone close to the person. Chin says these features do not prove Alzheimer’s disease.
What should happen after someone reports persistent changes?
Chin favors a thorough baseline assessment, consideration of other possible contributors, input from someone familiar with the person’s usual abilities when possible, and repeat testing over time. A qualified clinician can advise whether further evaluation is appropriate.
Source: beingpatient.com
